Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

1H-MRS at 4 Tesla in minimally treated early schizophrenia

Molecular Psychiatry volume 15, pages 629–636 (2010)Cite this article

Abstract

We investigated glutamate-related neuronal dysfunction in the anterior cingulate (AC) early in schizophrenia before and after antipsychotic treatment. A total of 14 minimally treated schizophrenia patients and 10 healthy subjects were studied with single-voxel proton magnetic resonance spectroscopy (1H-MRS) of the AC, frontal white matter and thalamus at 4 T. Concentrations of N-acetylaspartate (NAA), glutamate (Glu), glutamine (Gln) and Gln/Glu ratios were determined and corrected for the partial tissue volume. Patients were treated with antipsychotic medication following a specific algorithm and 1H-MRS was repeated after 1, 6 and 12 months. There were group × region interactions for baseline NAA (P=0.074) and Gln/Glu (P=0.028): schizophrenia subjects had lower NAA (P=0.045) and higher Gln/Glu (P=0.006) in the AC before treatment. In addition, AC Gln/Glu was inversely related to AC NAA in the schizophrenia (P=0.0009) but not in the control group (P=0.92). Following antipsychotic treatment, there were no further changes in NAA, Gln/Glu or any of the other metabolites in any of the regions studied. We conclude that early in the illness, schizophrenia patients already show abnormalities in glutamatergic metabolism and reductions in NAA consistent with glutamate-related excitotoxicity.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

Article 12 November 2020

Jo Ellen Wilson, Matthew F. Mart, … E. Wesley Ely

Article 13 May 2021

David S. Knopman, Helene Amieva, … David T. Jones

References

  1. Olney JW, Farber NB . Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 1995; 52: 998–1007.

    Article  CAS  PubMed  Google Scholar 

  2. Farber NB, Wozniak DF, Price MT, Labruyere J, Huss J, St Peter H et al. Age-specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia. Biol Psychiatry 1995; 38: 788–796.

    Article  CAS  PubMed  Google Scholar 

  3. Moghaddam B, Adams B, Verma A, Daly D . Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway for NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 1992; 17: 2921–2927.

    Article  Google Scholar 

  4. Reynolds LM, Cochran SM, Morris BJ, Pratt JA, Reynolds GP . Chronic phencyclidine administration induces schizophrenia-like changes in N-acetylaspartylglutamate in rat brain. Schizophr Res 2005; 73: 147–152.

    Article  PubMed  Google Scholar 

  5. Newcomer JW, Krystal JH . NMDA receptor regulation of memory and behavior in humans. Hippocampus 2001; 11: 529–542.

    Article  CAS  PubMed  Google Scholar 

  6. Rowland L, Bustillo J, Mullins P, Jung R, Lenroot R, Landgraf E et al. The effects of ketamine on anterior cingulate glutamate metabolism in healthy humans: a 4.0T proton MRS study. Am J Psychiatry 2005; 162: 394–396.

    Article  PubMed  Google Scholar 

  7. Theberge J, Bartha R, Drost DJ, Menon RS, Malla A, Takhar J et al. Glutamate and glutamine measured with 4.0T proton MRS in never-treated patients with schizophrenia and healthy volunteers. Am J Psychiatry 2002; 159: 1944–1946.

    Article  PubMed  Google Scholar 

  8. Chang L, Friedman J, Ernst T, Zhong K, Tsopelas ND, Davis K . Brain metabolite abnormalities in the white matter of elderly schizophrenic subjects: implication for glial dysfunction. Biol Psychiatry 2007; 62: 1396–1404.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Hashimoto K, Engberg G, Shimizu E, Nordin C, Lindström LH, Iyo M . Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naïve schizophrenic patients. BMC Psychiatry 2005; 5: 6.

    Article  PubMed  PubMed Central  Google Scholar 

  10. Bustillo J, Barrow R, Paz R, Tang J, Seraji-Bozorgzad N, Moore G et al. Long term treatment of rats with haloperidol: lack of an effect on brain N-acetyl aspartate levels. Neuropsychopharmacology 2006; 31: 751–756.

    Article  CAS  PubMed  Google Scholar 

  11. Bartha R, Drost DJ, Menon RS, Williamson PC . Comparison of the quantification precision of human short echo time (1)H spectroscopy at 1.5 and 4.0 Tesla. Magn Reson Med 2000; 44: 185–192.

    Article  CAS  PubMed  Google Scholar 

  12. Brooks WM, Friedman SD, Stidley CA . Reproducibility of 1H-MRS in vivo. Magn Reson Med 1999; 40: 193–197.

    Article  Google Scholar 

  13. Petropoulos H, Sibbitt Jr WL, Brooks WM . Automated T2 quantitation in neuropsychiatric lupus erythematosus: a marker of active disease. J Magn Reson Imaging 1999; 9: 39–43.

    Article  CAS  PubMed  Google Scholar 

  14. Ernst T, Kreis R, Ross BD . Absolute quantitation of water and metabolites in the human brain. 1. Compartments and water. J Magn Reson B 1993; 102: 1–8.

    Article  CAS  Google Scholar 

  15. Andreasen NC . Scale for the Assessment of Positive Symptoms (SAPS). University of Iowa, Iowa City, 1984.

  16. Andreasen NC . Scale for the Assessment of Negative Symptoms (SANS). University of Iowa, Iowa City, 1984.

  17. Simpson GM, Angus JW . A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 11–19.

    Article  CAS  PubMed  Google Scholar 

  18. Barnes TR . A rating scale for drug-induced akathisia. Br J Psychiatry 1989; 154: 672–676.

    Article  CAS  PubMed  Google Scholar 

  19. Guy W . ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. US Department of Health, Education and Welfare: Washington, DC, 1976 pp 534–537.

  20. Steen RG, Hamer RM, Lieberman JA . Measurement of brain metabolites by 1H magnetic resonance spectroscopy in patients with schizophrenia: a systematic review and meta-analysis. Neuropsychopharmacology 2005; 30: 1949–1962.

    CAS  PubMed  Google Scholar 

  21. Lindquist DM, Hawk RM, Karson CN, Komoroski RA . Effects of antipsychotic drugs on metabolite ratios in rat brain in vivo. Magn Reson Med 2000; 43: 355–358.

    Article  CAS  PubMed  Google Scholar 

  22. Bustillo J, Wolff C, Myers-Gutierrez A, Dettmer T, Cooper T, Allan A et al. Treatment of rats with antipsychotic drugs: lack of an effect on N acetyl-aspartate levels. Schizophr Res 2002; 1889: 1–9.

    Google Scholar 

  23. Magistretti PJ, Pellerin L . Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Phil Trans R Soc Lond 1999; 354: 1155–1163.

    Article  CAS  Google Scholar 

  24. Xu S, Yang J, Li C, Zhu W, Shen J . Metabolic alterations in focally activated primary somatosensory cortex of alpha-chloralose-anesthetized rats measured by H MRS at 11.7T. Neuroimage 2005; 28: 401–409.

    Article  PubMed  Google Scholar 

  25. Tibbo P, Hanstock C, Valiakalayil A, Allen P . 3-T proton MRS investigation of glutamate and glutamine in adolescents at high genetic risk for schizophrenia. Am J Psychiatry 2004; 161: 1116–1118.

    Article  PubMed  Google Scholar 

  26. Tebartz van Elst L, Valerius G, Buchert M, Thiel T, Rusch N, Bubl E et al. Increased prefrontal and hippocampal glutamate and concentration in schizophrenia: evidence from a magnetic resonance spectroscopy study. Biol Psychiatry 2005; 58: 724–730.

    Article  CAS  Google Scholar 

  27. Theberge J, Al-Semaan Y, Williamson PC, Menon RS, Neufeld RW, Rajakumar N et al. Glutamate and glutamine in the anterior cingulate and thalamus of medicated patients with chronic schizophrenia and healthy comparison subjects measured with 4.0-T proton MRS. Am J Psychiatry 2003; 160: 2231–2233.

    Article  PubMed  Google Scholar 

  28. Choe BY, Suh TS, Shinn KS, Lee CW, Lee C, Paik IH . Observation of metabolic changes in chronic schizophrenia after neuroleptic treatment by in vivo hydrogen magnetic resonance spectroscopy. Invest Radiol 1996; 6: 345–352.

    Article  Google Scholar 

  29. Fannon D, Simmons A, Tennakoon L, O'Ceallaiagh S, Sumich A, Doku V et al. Selective deficit of hippocampal N-acetylaspartate in antipsychotic-naïve patients with schizophrenia. Biol Psychiatry 2003; 54: 587–598.

    Article  CAS  PubMed  Google Scholar 

  30. Bustillo J, Lauriello J, Rowland L, Thomson L, Petropoulus H, Hammond R et al. Longitudinal follow-up of neurochemical changes during the first year of antipsychotic treatment in schizophrenia patients with minimal previous medication exposure. Schizophr Res 2002; 58: 313–321.

    Article  PubMed  Google Scholar 

  31. Bustillo J, Rowland L, Jung R, Brooks W, Qualls C, Hammond R et al. Proton magnetic resonance spectroscopy during initial treatment with antipsychotic medication in schizophrenia. Neuropsychopharmacology 2008; 33: 2456–2466.

    Article  CAS  PubMed  Google Scholar 

  32. Theberge J, Williamson KE, Aoyama N, Drost DJ, Manchanda R, Malla AK et al. Longitudinal grey-matter and glutamatergic losses in first-episode schizophrenia. Br J Psychiatry 2007; 191: 325–334.

    Article  PubMed  Google Scholar 

  33. Baldessarini RJ, Hegarty JD, Bird ED, Benes FM . Meta-analysis of postmortem studies of Alzheimer's disease-like neuropathology in schizophrenia. Am J Psychiatry 1997; 154: 861–863.

    Article  CAS  PubMed  Google Scholar 

  34. Glantz L, Lewis D . Decreased dendritic spine density on prefrontal cortical pyramidal neurons in schizophrenia. Arch Gen Psychiatry 2000; 57: 65–73.

    Article  CAS  PubMed  Google Scholar 

  35. Lentz M, Kim J, Westmoreland S, Greco J, Fuller R, Ratai E et al. Quantitative neuropathologic correlates of changes in ratio of N-acetylaspartate to creatine in macaque brain. Radiology 2005; 235: 461–468.

    Article  PubMed  Google Scholar 

  36. Hajszan T, Leranth C, Roth RH . Subchronic phencyclidine treatment decreases the number of dendritic spine synapses in the rat prefrontal cortex. Biol Psychiatry 2006; 60: 639–644.

    Article  CAS  PubMed  Google Scholar 

  37. Matute C, Melone M, Vallejo-Illarramendi A, Conti F . Increased expression of the astrocytic glutamate transporter GLT-1 in the prefrontal cortex of schizophrenics. Glia 2005; 49: 451–455.

    Article  PubMed  Google Scholar 

  38. Gluck MR, Thomas RG, Davis KL, Haroutunian V . Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients. Am J Psychiatry 2002; 159: 1165–1173.

    Article  PubMed  Google Scholar 

  39. López-Gil X, Babot Z, Amargós-Bosch M, Suñol C, Artigas F, Adell A . Clozapine and haloperidol differently suppress the MK-801-increased glutamatergic and serotonergic transmission in the medial prefrontal cortex of the rat. Neuropsychopharmacology 2007; 32: 2087–2097.

    Article  PubMed  Google Scholar 

  40. Lim KO, Hedehus M, Moseley M, de Crespigny A, Sullivan EV, Pferfferbaum A . Proton magnetic resonance imaging of cortical gray and white matter in schizophrenia. Arch Gen Psychiatry 1998; 55: 346–352.

    Article  CAS  PubMed  Google Scholar 

  41. Pfefferbaum A, Sullivan EV, Hedehus M, Moseley M, Lim KO . Brain gray and white matter transverse relaxation time in schizophrenia. Psychiatry Res 1999; 91: 93–100.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by the Mental Illness and Neuroscience Discovery Institute (DE-FG03-99ER62764/A002) and by the NIMH R01MH084898 to J Bustillo, MD. Dr Brooks is supported in part by the NIH Grant NS039123. The authors are grateful to Ranee Barrow, Tara Biehl, Heather Hawk, Elma Landgraf, Erica Snider, Catie Snyder, Mariebeth Velasquez and Christina Wolff for their contribution to this study.

Author information

Authors and Affiliations

  1. Department of Psychiatry, University of New Mexico, Albuquerque, NM, USA

    J R Bustillo, H Chen, R Hammond & J Lauriello

  2. Department of Neurosciences, University of New Mexico, Albuquerque, NM, USA

    J R Bustillo

  3. Maryland Psychiatric Research Center, University of Maryland, Baltimore, MD, USA

    L M Rowland

  4. The Mental Illness and Neuroscience Discovery Institute, Albuquerque, NM, USA

    P Mullins & R Jung

  5. Department of Psychology, University of New Mexico, Albuquerque, NM, USA

    R Jung

  6. Department of Neurology, University of New Mexico, Albuquerque, NM, USA

    R Jung

  7. Department of Mathematics & Statistics, University of New Mexico, Albuquerque, NM, USA

    C Qualls

  8. Department of Neurology, Hoglund Brain Imaging Center, University of Kansas Medical Center, Kansas City, KS, USA

    W M Brooks

Authors
  1. J R Bustillo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L M Rowland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P Mullins
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R Jung
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. H Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. C Qualls
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. R Hammond
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. W M Brooks
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. J Lauriello
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J R Bustillo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on the Molecular Psychiatry website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bustillo, J., Rowland, L., Mullins, P. et al. 1H-MRS at 4 Tesla in minimally treated early schizophrenia. Mol Psychiatry 15, 629–636 (2010). https://doi.org/10.1038/mp.2009.121

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/mp.2009.121

Keywords

This article is cited by

Search

Advanced search

Quick links